Zhai et al. reported that primary resistance to sorafenib might be due to genetic heterogeneity; nonetheless, activation of compensatory pathways such as PI3K/Akt and JAK/STAT pathways, tumor hypoxia, and EMT by sorafenib can lead to acquired resistance35. Here, AKT1 is linked to neoplasm.